Abstract
We reviewed the status of prostate cancer diagnosis in Western Australia (WA) with the aim of improving decision-making about PSA testing and prostate biopsy. Our patient cohort was 5145 men undergoing an initial biopsy for prostate cancer diagnosis in WA between 1998 and 2004. Transrectal ultrasound-guided biopsies were performed by one of 18 clinicians whereas all pathology was assessed by one urological pathologist. Cancer detection rates were 59% for initial biopsies and 32% for repeat biopsies. High-grade cancer (Gleason sum ⩾7) accounted for 69 and 38% of tumours diagnosed on initial and repeat biopsy, respectively. The rates of cancer diagnosis and detection of high-grade tumours were both 1.6-fold higher in WA patients compared with those obtained at baseline screening of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial of US men (P<0.001). These higher than expected rates of cancer detection and high histological grade indicate that urological practice in WA between 1998 and 2004 was significantly more conservative than US practice over this time period, probably leading to underdiagnosis of prostate cancer. Our findings may be relevant to other countries where urological practice differs from that in the United States.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Urological Society of Australia and New Zealand. PSA testing policy 2009 2009. Available at: http://www.usanz.org.au/uploads/29168/ufiles/USANZ_2009_PSA_Testing_Policy_Final1.pdf. Accessed November 2009.
American Urological Association, Education and Research Inc. Prostate-specific antigen best practice statement: 2009 Update 2009. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed November 2009.
Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319.
Schröder FH, Hugosson J, Roobol MJ, Tamella TLJ, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a rancomized European study. N Engl J Med 2009; 360: 1320–1328.
Bastian PJ, Mangold LA, Epstein JI, Partin AW . Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004; 101: 2001–2005.
Epstein JI, Walsh PC, Carmichael M, Brendler CB . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368–374.
Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433–438.
Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE . Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men. Med J Aust 1999; 171: 185–188.
Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Agius PA et al. Men in Australia telephone survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2006; 366: 218–224.
Postma R, Shröder FH, van Leenders GJLH, Hoedemaeker RF, Vis AN, Roobol MJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)—section Rotterdam: a comparison of two rounds of screening. Eur Urol 2007; 52: 89–97.
Allsbrook Jr WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI . Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologists. Hum Pathol 2001; 32: 81–88.
Presti Jr JC . Prostate biopsy strategies. Nat Clin Pract Urol 2007; 4: 505–511.
Hong YM, Lai FC, Chon CH, McNeal JE, Presti JC . Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22: 7–10.
Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A . Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urologic practice. BJU Int 2005; 95: 545–548.
Stapleton AMF, Johns RL, Kopsaftis T, Tamblyn J . Abnormal PSA tests: delays in referral. Aust Fam Physician 2008; 37: 84–88.
O'Dowd GJ, Miller MC, Orozco R, Veltri RW . Analysis of repeated biopsy results within one year after a noncancer diagnosis. Urology 2000; 55: 553–559.
Lowe FC, Gilbert SM, Kahane H . Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324 684 biopsies performed between 1995 and 2002. Urology 2003; 62: 1045–1049.
Maffezzini M, Gavazzi L, Calcagno T, Capponi G, Bandelloni R . Still a place for the classical systematic sextant technique? Cancer detection rates and complications in 1025 consecutive prostatic biopsies. Arch Ital Urol Androl 2005; 77: 106–108.
Lienert AR, Davidson PJ, Wells JE . The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population. NZMJ 2009; 122: 39–50.
Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW et al. Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J 2008; 2: 518–523.
Scales Jr CD, Antonelli J, Curtis LH, Schulman KA, Moul JW . Prostate-specific antigen screening among young men in the United States. Cancer 2008; 113: 1315–1323.
Beulac JA, Fry RN, Onysko J . Lifetime and recent prostate-specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006; 97: 171–176.
Zappa M, Visioli C, Crocetti E, Buonamici C, Baccini A, Taddei S et al. Practice of opportunistic PSA screening in the Florence district. Eur J Cancer Prev 2003; 12: 201–204.
Ciatto S, Houssami N, Martinelli F, Giusti F, Zappa M . PSA use and incidence of prostate biopsy in the Tuscany region: is opportunistic screening discounting biopsy in subjects with PSA elevation? Tumori 2008; 94: 518–522.
Sneyd MJ, Cox B, Paul C, Skegg CG . PSA testing and digital rectal examination in New Zealand. Aust NZ J Public Health 2003; 27: 502–506.
Gibbons L, Waters C . Prostate cancer—testing, incidence, surgery and mortality. Health Rep 2003; 14: 9–20.
Grubb III RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524–1530.
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584–591.
Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A . Extent of prostate-specific antigen contamination in the Spanish section of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2006; 50: 1234–1240.
Acknowledgements
The West Australian Prostate Biopsy Database and Abbott-West Australian Radical Prostatectomy Databases are supported by the Prostate Cancer Foundation of Australia and Abbott Australasia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
O'Brien, B., Brown, A., Shannon, T. et al. Prostate biopsy in Western Australia 1998–2004. Prostate Cancer Prostatic Dis 13, 263–269 (2010). https://doi.org/10.1038/pcan.2010.7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2010.7